Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes
June 10, 2019 08:05 ET
|
Diasome Pharmaceuticals, Inc.
Hepatic safety also confirmed over six months of treatment with mealtime liver targeted insulin Company focused on Phase 3 initiation in 2020 CLEVELAND, June 10, 2019 (GLOBE NEWSWIRE) -- Diasome...
Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions
May 29, 2019 10:05 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, May 29, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., today announced upcoming presentations of an abstract highlighting data from the company’s Phase 2b ISLE-1 clinical trial...
Diasome Announces First Patient Enrolled in Phase 2 Study of Hepatocyte Directed Vesicle Nanotechnology for People with Type 1 Diabetes
March 28, 2019 10:03 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, March 28, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing hepatocyte directed vesicle (HDV) nanotechnology that can be added...
Diasome Provides Company Update
February 14, 2019 10:04 ET
|
Diasome Pharmaceuticals, Inc.
CLEVELAND, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing hepatocyte directed vesicle (HDV) nanotechnology as an insulin...